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Case report
Autoimmune polyendocrine syndrome type 1 (APS-1),  or autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare, autosomal 
recessive autoimmune disease caused by a mutation of the autoimmune regulator 
(AIRE) gene. The main symptom triad in APS-1 comprises chronic mucocutaneous 
candidiasis, adrenal insufficiency, and hypoparathyroidism. Various autoimmune 
diseases and ectodermal abnormalities are also commonly associated with the 
syndrome. The treatment of APS-1 includes hormone replacement and symptom 
control. It is important to monitor such patients for clinical manifestations of their 
disease through regular follow-up. We report the case of a 10-year-old Korean girl 
with APS-1 due to a novel compound heterozygous mutation of the AIRE gene. 
This patient's main clinical manifestations were adrenal insufficiency and chronic 
mucocutaneous candidiasis. The patient had a previously known pathogenic variant 
of c.1513delG (p.Ala505ProfsTer16), and a newly discovered variant of c.1360dupC 
(p.His454ProfsTer50).
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Autoimmune polyendocrine syndrome type 1 (APS-1), or autoimmune polyendo-
crinopathy-candidiasis-ectodermal dystrophy (OMIM 240300), is a rare autosomal recessive 
autoimmune disease. This disease is caused by loss-of-function mutations in the autoimmune 
regulator (AIRE) gene. The AIRE gene is located on chromosome 21q22.3 and encodes a 
545-amino acid protein.1) AIRE promotes ectopic expression of tissue-specific antigens in 
thymic medullary epithelial cells and lymph nodes, which regulate negative selection of 
autoreactive T effector cells.2,3) Mutations in the AIRE gene result in decreased peripheral 
tissue antigen expression in the thymus. This absence ultimately leads to failure to delete the 
autoreactive T lymphocytes that target peripheral antigens.4)
APS-1 is clinically diagnosed by the presence of at least 2 symptoms in the classic triad, as 
follows: chronic mucocutaneous candidiasis, adrenal insufficiency (Addison disease), and 
hypoparathyroidism. The following autoimmune diseases may also occur in APS-1: type 
1 diabetes mellitus, hypothyroidism, gonadal failure, autoimmune hepatitis, autoimmune 
gastritis, pernicious anemia, and ectodermal abnormalities (alopecia, vitiligo, keratitis, 
nail dystrophy, and enamel dysplasia).5,6) Due to its diverse symptoms and variable disease 
course, the clinical phenotype can differ between patients even within the same family. This 
phenotypic variability makes it difficult to specifically diagnose APS-1.5,7,8)
The global prevalence of APS-1 is very low, with only 500 cases reported worldwide. There 
is a higher prevalence of disease in certain populations, including Iranian Jews (1:9,000),9) 
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Sardinia (1:14,400),10) and Finland (1:25,000).6) In contrast, 
APS-1 is very rare in east Asia.11,12) There are no reported data 
regarding its prevalence in Korea.
Here, we report a case of APS-1 in a 10-year-old Korean 
girl with a novel compound heterozygous mutation of the 
AIRE gene. Our patient’s main clinical manifestations included 
adrenal insufficiency and chronic mucocutaneous candidiasis.
Case report
A 10-year-old girl, born of nonconsanguineous parents, 
presented with poor oral intake and vomiting for 3 days. She 
also had general weakness, lethargy, and excessive sweating 
during the same period. She was born through a normal vaginal 
delivery at 40 weeks gestation, weighing 3.25 kg. There were no 
complications during pregnancy or delivery. The patient had 
no family history of chronic illness, including autoimmune 
diseases. However, she had a personal history of recurrent 
episodes of oral candidiasis since 6 months of age, for which 
she occasionally applied topical antifungal medications. 
She also had history of enamel dysplasia of the teeth, which 
was confirmed by dental examination at age 8. On physical 
examination, she had hyperpigmentation on the lip and 
fingertips. These findings had first appeared one month prior to 
presentation. The patient's heart rate during the initial visit was 
99 beats/min, with a blood pressure of 91/68 mmHg (10th–25th 
percentile). She was 135 cm tall (25th–50th percentile) with a 
weight of 26.3 kg (10th–25th percentile), and BMI of 14.43 kg/
m2 (5th–10th percentile).
There were no abnormal findings on initial laboratory tests, 
including complete blood cell count and routine chemistry 
(Table 1). The serum sodium level was 134 mmol/L, and the 
potassium was 4.7 mmol/L. Hormone studies were suggestive 
of adrenal insufficiency, with an adrenocorticotropic hormone 
(ACTH) level of 1,182.0 pg/mL, and cortisol < 0.4 μg/dL. On 
a synthetic ACTH stimulation test, the peak cortisol level was 
0.6 μg/dL. Therefore, the patient was diagnosed with primary 
adrenal insufficiency. Other basal hormone levels were within 
normal ranges (Table 2). The serum parathyroid hormone 
(PTH) level was 61.7 pg/mL, which is also within normal 
range. Oral hydrocortisone was started at a dose of 15 mg/
m2. Several additional studies were performed to evaluate 
the etiology of adrenal insufficiency. A chromosome study 
showed a normal female karyotype with 46, XX. There were 
no remarkable findings on pelvic ultrasound or magnetic 
resonance imaging of the sella. A very long-chain fatty acid 
test for adrenoleukodystrophy was negative. The adrenal 
cortex antibody test was also negative. Genetic analysis did not 
identify any mutations in the StAR or POR genes. However, 
whole-exome sequencing (WES) revealed a compound 
heterozygous mutation in the AIRE gene. WES was performed 
using the TruSight One panel of 4,813 genes (Illumina, San 
Diego, CA, USA) for screening for pathologic mutations. One 
of the mutations was previously reported, while the other was 
novel. The previously known pathogenic variant is c.1513delG 
(p.Ala505ProfsTer16).13) The newly discovered variant is 
c.1360dupC (p.His454ProfsTer50) (phyloP/phastCons score 
3.041/1) (http://compgen.cshl.edu/phast/index.php), which is a 
mutation of an evolutionarily conserved site (Fig. 1). The variant 
was neither found in ExAC (http://exac.broadinstitute.org/) 
nor 1,000 genomes (http://phase3browser.1000genomes.org). 
The patient's parents also underwent genetic screening. Both 
her father and mother were carriers of each mutation, which 
confirmed the etiology of APS-1 in this patient.
Table 1. Initial laboratory study findings
Variable Value Reference range
WBC count (103/μL) 6.46 4.0–10.8
Hemoglobin (g/dL) 14.1 14.0–18.0
Hematocrit (%) 40.9 40.0–50.0
Platelet count (103/μL) 349 150.0–400.0
Calcium (mg/dL) 9.6 8.8–10.8
Inorganic phosphate (mg/dL) 5.5 3.9–5.8
Glucose (mg/dL) 95 70–110
BUN (mg/dL) 10.7 7–17
Creatinine (mg/dL) 0.44 0.37–0.72
Total protein (g/dL) 6.8 6.0–8.0
Albumin (g/dL) 4.1 3.8–5.4
Alkaline phosphatase (IU/L) 202 144–386
AST (IU/L) 41 13.0–34.0
ALT (IU/L) 28 5.0–46.0
Total bilirubin (mg/dL) 0.3 0.2–0.8
Na (mmol/L) 134 135.0–145.0
K (mmol/L) 4.7 3.5–5.5
Cl (mmol/L) 102 98–110
tCO2 (mmol/L) 17 20–30
WBC, white blood cell; BUN, blood urea nitrogen; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase.
Table 2. Basal hormone levels of our patient on age 10
Variable Value Reference range
LH (mIU/mL) <0.2 0.02–4.7
FSH (mIU/mL) 0.4 1.0–10.8
Prolactin (ng/mL) 7.1 3–24
Estradiol (pg/mL) <8.0 1.0–2.4
Testosterone (ng/dL) <2.5 7–28
TSH (μIU/mL) 1.67 0.35–4.94
T3 (ng/mL) 1.21 0.58–1.59
Free T4 (ng/dL) 1.10 0.70–1.48
ACTH (pg/mL) 1,182.00 7.2–63.3
Cortisol (μg/dL) <0.4 6.7–22.6
17-OH-progesterone (ng/mL) 0.06 0.11–1.08
Renin (ng/mL/hr) 29.76 0.5–3.3
Aldosterone (pg/mL) 74.54 40–480
PTH (pg/mL) 61.7 15–65
LH, luteinizing hormone; FSH, follicle stimulating hormone; TSH, 
thyroid-stimulating hormone; ACTH, adrenocorticotropic hormone; 
PTH, parathyroid hormone.
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Discussion
APS-1 is a rare, autosomal recessive autoimmune disease 
that is caused by AIRE gene mutations. Today, more than 
100 mutations of the AIRE gene have been reported in APS-
1 patients worldwide.14) Patients can be homozygous for both 
mutant alleles. Alternatively, there may be 2 independent 
mutations that lead to APS-1, Which was the case in our patient. 
The patient described here had a compound heterozygous 
mutation of the AIRE gene. Parental screening revealed that 
one mutation had originated from each parent. Mutation of 
c.1513delG was previously reported in 2 Japanese siblings, 
who were born to a Japanese mother and a Korean father.13) In 
addition, a novel mutation (c.1360dupC) was found, which led 
to a frameshift mutation at codon 454 that created premature 
truncation.
APS-1 is characterized by the following 3 main clinical fea-
tures: chronic mucocutaneous candidiasis, adrenal insufficiency, 
and hypoparathyroidism. Our patient had recurrent episodes 
of candidiasis since she was 6 months old. She was diagnosed 
with dental enamel dysplasia at 8 years old and presented with 
adrenal insufficiency at age 10.
Chronic mucocutaneous candidiasis is the most common 
initial symptom in APS-1 patients. Candida typically colonizes 
the oral mucosa and diaper area during infancy, and later 
spreads to the vulvovaginal area, intestine, and nails.15) Chronic 
oral candidiasis should be treated aggressively, because 
uncontrolled candidiasis is associated with increased risk of 
esophageal strictures and squamous cell carcinoma of the oral 
mucosa or esophagus.16) Therefore, it is important that these 
patients maintain good oral hygiene, and receive antifungal 
(topical) prophylaxis especially in cases of recurrent episodes of 
candidiasis.
Adrenal insufficiency is often diagnosed when the patient 
presents in adrenal crisis with rather nonspecific symptoms 
and signs. Patients with adrenal insufficiency usually present 
to the hospital complaining of general weakness, fatigue, 
vomiting, abdominal pain, and hyperpigmentation (similar 
to our case). Adrenal insufficiency is caused by a lack of 
adrenal hormones, including cortisol, aldosterone, and adrenal 
androgens. Glucocorticoid replacement therapy is required in 
all patients with adrenal insufficiency, and is usually treated with 
physiologic doses of hydrocortisone (10 to 15 mg/m2/day).15) 
It is also important to educate patients and families about 
managing adrenal insufficiency with "stress doses" according to 
the patient’s general condition.
Hypoparathyroidism is another classic manifestation 
of APS-1. The patient in our case did not have features of 
hypoparathyroidism. The incidence of hypoparathyroidism 
in APS-1 increases with age. One-third of APS-1 patients are 
diagnosed with hypoparathyroidism at age 5, two-thirds at 
10 years old, and 85% at age 30.5) The patient in our case is 10 
years old; therefore, regular follow-up with laboratory studies is 
necessary to monitor for signs of hypoparathyroidism, including 
hypocalcemia, hyperphosphatemia, and low serum PTH.
Patients with APS-1 require regular follow-up and close 
monitoring for the development of autoimmune diseases 
by pediatric endocrinologists. Autoimmune gonadal failure 
develops more often in female patients, who present with 
amenorrhea, irregular menstrual periods, and infertility.5) 
Patients also must be screened regularly for type 1 diabetes 
mellitus, hypothyroidism, autoimmune hepatitis , and 
Fig. 1. Direct sequencing of the patient's AIRE gene.
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autoimmune gastritis. Diverse ectodermal dystrophies are 
commonly found in APS-1 patients. Enamel hypoplasia of 
the permanent teeth, which our patient presented with at age 
8, is seen in up to 77% of APS-1 patients.6) Other ectodermal 
abnormalities including alopecia, vitiligo, keratitis, and nail 
dystrophy, also occur frequently in APS-1.
Currently, various autoantibody tests are used in the diagnosis 
and follow-up of APS-1 patients. In particular, autoantibodies 
against interferon (α, ω) provide high sensitivity and 
specificity in screening for APS-1.17) Our patient had negative 
adrenal cortex antibody test results, which occurs in ~10% 
of autoimmune adrenal insufficiency.18) Additional studies, 
including autoantibodies to interferon and organ specific 
antibodies, ought to be considered to monitor for additional 
autoimmune diseases.
The guidelines and clinical recommendations for APS-1 are 
insufficient given its rarity. Currently, the standard therapeutic 
options of APS-1 include hormone replacement and symptom 
control based on a clinician’s personal experience. Treatment 
with immunosuppressive agents, such as cyclosporine, metho-
trexate, and methylprednisolone is being investigated.19) Future 
investigations are needed regarding genetic background, 
immune tolerance, and disease progress to optimize diagnosis 
and management of APS-1 patients.
It is important to differentially diagnose APS-1 from other 
autoimmune polyendocrine syndromes, such as autoimmune 
polyendocrine syndrome type 2 (APS-2), immune dysfunction, 
polyendocrinopathy, enteropathy, and X-linked (IPEX) 
syndrome. APS-2 is a polygenic disorder which has a complex 
inheritance pattern with a strong linkage to the human 
leukocyte antigen locus. APS-2 is defined by the presence of 
at least 2 of the following 3 diseases: type 1 diabetes mellitus, 
adrenal insufficiency, and autoimmune thyroid disease.20) IPEX 
syndrome is a rare X-linked recessive disorder, which commonly 
presents with chronic diarrhea, type 1 diabetes mellitus, and 
eczematous dermatitis. It is caused by mutation in the FOXP3 
gene, resulting in hyperactive T cells with both autoimmune 
and allergic manifestations.20) Detailed history taking and 
physical exam with proper genetic studies are necessary for 
discriminating APS-1 from APS-2 and IPEX syndrome.
Our patient first presented with symptoms of adrenal insuffi-
ciency, and several tests were performed but the etiology was 
unclear until the WES analysis. Hereafter, when we encounter 
adrenal insufficiency patients with unknown etiology, keeping 
the possibility of APS-1 in mind would be helpful in early 
diagnosis and appropriate patient management.
In conclusion, we report a novel compound heterozygous 
mutation of  the AIRE gene in a patient with APS-1. The 
patient presented with adrenal insufficiency, and had a history 
of chronic mucocutaneous candidiasis and dental enamel 
dysplasia. Further analysis including functional studies and 
regular follow-up are required.
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